COVID-19 中的优势免疫原性抗体胚系。
Immunodominant antibody germlines in COVID-19.
机构信息
Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Faculty of Medicine, Imperial College, London, UK.
出版信息
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20210281.
Abstract
The neutralizing antibody response to SARS-CoV-2 is dominated by antibodies deriving from germlines IGHV3-53/IGHV3-66, which are also associated with self-reacting antibodies. Could vaccines avoid the expansion of this immunodominant response, decrease the risk of autoimmunity, and still protect against emerging SARS-CoV-2 variants?
摘要
针对 SARS-CoV-2 的中和抗体反应主要由源自 IGHV3-53/IGHV3-66 胚系的抗体主导，这些抗体也与自身反应性抗体有关。疫苗能否避免这种免疫优势反应的扩大，降低自身免疫的风险，同时仍然能预防新出现的 SARS-CoV-2 变体？
Zotero 插件